Industry Updates for the Psychedelics World | Page 9 of 35

Psychedelics News

Industry

4 May 2023

First Patient Dosed in Beckley Psytech’s Phase 2a Study for Treatment Resistant Depression

Beckley Psytech, a major private psychedelic medicine firm, has moved its Phase 2 study forward and begun dosing patients for Treatment-Resistant Depression....

By Microdose NewsDesk

Industry

3 May 2023

MindMed Drama: Freemans Attempt Board of Directors Takeover

The drama continues at MindMed. The (former?) fan-favorite has had a rough run, facing an industry-wide drop in share price while dealing with a string of scenarios that have (rightly...

By Jason Najum

Industry

2 May 2023

Albert Labs Receives Acceptance of 35 Patent Claims for Manufacturing Technology

Albert Labs International Corp. (CSE: ABRT) (the "Company" or "Albert Labs"), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs, is pleased to...

By Microdose NewsDesk

Industry

2 May 2023

American Medical Association to Issue First Code for Psychedelic Therapies to COMPASS and MAPS

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and MAPS Public Benefit Corporation (MAPS PBC), a...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

20 Apr 2023

Intiem Secures Intellectual Property Rights for AI-Driven VR Platform Featuring AI Virtual Sexual Wellness Therapists

Intiem, a leading technology company focused on sexual wellness, is pleased to announce that it has secured the intellectual property rights for an AI-driven VR platform featuring AI Virtual Sexual...

By Microdose

Industry

18 Apr 2023

Atai Partner IntelGenx Announces FDA Approval of Oral Film

Under-the-radar firm IntelGenx has just received FDA approval....

By Microdose NewsDesk

Industry

18 Apr 2023

LSD Decreased Depression Symptoms by 50% in New MindMed Study

On April 14th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO: MMED) released preliminary data from a Phase 2 clinical trial, which attempted to treat Major Depressive Disorder (MDD) with LSD-assisted...

By James Hallifax

Industry

14 Apr 2023

MindMed Announces Positive Data from Phase 2 LSD Trial for Depression

One of MindMed’s most valuable assets is its deal with the University Hospital Basel and its research team led by Dr....

By Microdose NewsDesk

Industry

14 Apr 2023

Atai Starts New Phase 1 Study of PCN-101 (R-Ketamine)

Back in January, atai Life Sciences released results for its most advanced program: PCN-101 (using R-Ketamine for Treatment-Resistant Depression) Unfortunately for patients and investors, results were somewhat disappointing and “did...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result